Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) [Phase 3]

View source ↗

Summary

This update reports the completion and posted results from the Phase 3 MK-3475-091/KEYNOTE-091 trial comparing pembrolizumab to placebo as adjuvant therapy afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-02-15